Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Entrepreneurship Guest Lecture Series

Publication date: Aug 28, 2012 02:11 PM

Start: Nov 01, 2012 05:15 PM

[image reference is broken]

Speaker: Jack Jackmann - CEO, DRFP Holdings Limited
DRFP is a materials science company that has developed a new polymer for dental and medical applications that has disruptive potential. The company currently operates in the UK and will enter the US market this year